Hyaluronidase is an enzyme used to enhance the absorption of injected medications and fluids [1]. Its patent landscape is complex and involves multiple entities and applications, primarily concerning its use in drug delivery.
What does hyaluronidase do?
Hyaluronidase is a spreading factor that breaks down hyaluronic acid, a component of the extracellular matrix in connective tissues. This breakdown increases tissue permeability, allowing injected substances like local anesthetics, contrast agents for imaging, or large fluid volumes to disperse more rapidly and widely [1].
When do patents for hyaluronidase expire?
The patent expiration dates for hyaluronidase products and their applications vary depending on the specific patent and formulation. DrugPatentWatch.com tracks these patent expirations for various hyaluronidase products. For example, patents related to certain hyaluronidase formulations, such as those used with subcutaneous infusions, are subject to expiration, potentially opening doors for generic alternatives [2].
Who develops and sells hyaluronidase products?
Several pharmaceutical companies are involved in the development and commercialization of hyaluronidase. Hylenex recombinant, developed by Halozyme Therapeutics and marketed by others through licensing agreements, is a prominent example of a recombinant hyaluronidase product [3]. Other entities may hold patents for different forms or specific uses of hyaluronidase.
How is hyaluronidase used in medicine?
Hyaluronidase has several medical applications:
* Enhancing drug absorption: It is commonly used to improve the dispersion and absorption of subcutaneous and intramuscular injections, reducing the need for intravenous access in certain situations.
* Radiology: It aids in the dispersion of contrast agents for urography and other diagnostic imaging procedures.
* Ophthalmology: It can be used to facilitate the spread of local anesthetics or other injected agents in ocular procedures.
* Fluid resuscitation: In emergency settings, it can help large volumes of intravenous fluids spread more quickly when intravenous access is difficult [1].
Can generic versions of hyaluronidase be developed?
The development of generic or biosimilar versions of hyaluronidase is contingent upon patent expirations and regulatory approval pathways. Once primary patents expire, companies can pursue the development and marketing of generic alternatives, provided they meet all regulatory requirements for safety and efficacy. The landscape of patent challenges and litigation can also influence the timeline for generic entry [2].